Results 211 to 220 of about 1,950,206 (296)

The Origins of Allergy: An Outside‐In, Bioenergetic Hypothesis

Allergy, EarlyView.
ABSTRACT Allergic disease has risen too rapidly for inherited susceptibility to explain it, and the risk variants so far reported lie in the epithelial barrier and in type‐2 immunity. We propose a five‐layer model in which epithelial barrier and bioenergetic dysfunction may precede and promote type‐2 immune deviation rather than arise solely as its ...
Peter K. Smith, Nicholas P. West, Stanley Du Preez, Hugh A. Sampson, Peter W. Hellings, David Price, Liam O'Mahony, Carina Venter, Cezmi A. Akdis, Gil Yosipovitch   +9 more
wiley   +1 more source

Synthesis and characterization of chitosan-grafted-dopamine based micelles as multifunctional nanomedicines for Parkinson's disease treatment by intranasal administration. [PDF]

Drug Deliv Transl Res
Trapani A, Carbone A, Gioia SD, Fracchiolla G, Soccio P, Perna FM, Quivelli AF, Suranna GP, Grisorio R, Porto CL, Conelli D, Colangelo G, Conese M.   +12 more
europepmc   +1 more source

Clarifying the Distinction Between Inclining Moral Bioenhancement and Prohibitory Moral Bioenhancement, and Their Effects on Freedom

Bioethics, EarlyView.
ABSTRACT The project of Moral Bioenhancement (MBE)—biomedical interventions causing individuals to have better moral beliefs, motivations, or behaviours—is controversial, particularly as MBE relates to human freedom. Proponents argue that MBE is utility‐promoting and compatible with freedom.
Daniel Lee
wiley   +1 more source

Intranasal administration of a panreactive influenza antibody reveals Fc-independent mode of protection. [PDF]

Sci Rep
Beukenhorst AL, Rice KL, Frallicciardi J, Koldijk MH, Boudreau CM, Crawford J, Cornelissen LAHM, da Costa KAS, de Jong BA, Fischinger S, Julg B, Klap JM, Koch CM, Magyarics Z, Mohamed FAN, Okonkwo V, Adams L, McCarthy CM, Ronsard L, Temperton N, Vietsch H, Wichapong K, Ziere B, Lingwood D, Goudsmit J.   +24 more
europepmc   +1 more source

Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α‐synuclein preformed fibrils‐induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines

Brain Pathology, EarlyView.
Omics‐driven drug repositioning reveals pyroxamide as a neuroprotective HDAC1 inhibitor in Parkinson's disease models. Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder mainly characterized by the degeneration of dopaminergic neurons originating in the substantia nigra (SN) pars compacta and projecting to other ...
Paz Cartas‐Cejudo, Marina De Miguel, Leire Extramiana, Mercedes Lachén‐Montes, Silvia Romero‐Murillo, Djordje Gveric, Joaquín Fernández‐Irigoyen, Enrique Santamaría   +7 more
wiley   +1 more source

Intranasal administration of stem cell derivatives for the treatment of AD animal models: a systematic review and meta-analysis. [PDF]

Stem Cell Res Ther
Hua Z, Zhou N, Zhou Z, Fu Z, Guo R, Akogo HY, Yang J, Yu M, Jiang Y, Lan S, Chang H, Ma J, Cui H.   +12 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Design, optimization of Niosomal gel capability for solubility and bioavailability enhancement of Kynurenic acid after intranasal administration: In Vitro and In Vivo Evaluation. [PDF]

BMC Biotechnol
Chettupalli AK, Bukke SPN, Abdul Rahaman S, Bodige M, Kanakaraju VK, Kavitha M, Srinivasarao D, Mohammed A, Goruntla N, Yadesa TM.   +9 more
europepmc   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

Intranasal Administration of KCNN2 Blocking Peptide Improves Deficits in Cognitive Flexibility in Mouse Model of Fetal Alcohol Spectrum Disorders. [PDF]

Int J Neuropsychopharmacol
Mohammad S, Wang L, Torii M, Hashimoto-Torii K.   +3 more
europepmc   +1 more source